$90 Million to Accelerate Clinical Development

Epicrispr Biotechnologies has raised $90 million in a Series C round co-led by Octagon Capital and Genesis Henderson Investors. Sanofi Ventures and others also participated. The funds will be used to expand clinical trials for EPI-321 in facioscapulohumeral muscular dystrophy (FSHD) and to develop its follow-on pipeline. This large-scale fundraising, following a $68 million Series B in 2025, was driven by early patient data that highlighted the clinical potential of epigenetic editing. However, this investment is equity-based venture financing, not revenue or pharma licensing, so future value will depend on clinical reproducibility.

EPI-321 Silences DUX4 Without DNA Cleavage

EPI-321 is an investigational AAVrh74-based gene therapy with no separate brand name, targeting DUX4 transcription factor and the D4Z4 repeat region, central to FSHD pathology. It is designed to deliver a non-cutting dCasONYX and epigenetic modulator to muscles, restoring CpG methylation in D4Z4 and suppressing toxic DUX4 expression. Unlike RNAi candidates requiring repeated dosing, EPI-321 aims for sustained inhibition after a single intravenous administration without permanent DNA cleavage. The U.S. FDA approved the Investigational New Drug (IND) application on April 3, 2025, and granted Fast Track designation. The current development stage is Phase 1/2.

Early Muscle Growth Signals and Interpretation Boundaries

The open-label, dose-escalation Phase 1/2 trial (NCT06907875) is evaluating safety, tolerability, and biological activity in 12 adult FSHD1 patients. The first three patients in the low-dose group, who could be assessed after six months, showed an average increase of approximately 370 mL in non-fat muscle volume, equivalent to about 0.8 pounds, with individual gains ranging from 0.5 to 1.3 pounds. As of May 12, 2026, nine patients had been dosed across two dose groups with no serious adverse events reported, and enrollment and dosing for all 12 patients were completed. However, the absence of a control group and the small sample size of three patients for efficacy analysis means that functional improvement and the durability of DUX4 suppression must be validated in more patients and long-term follow-up.

Intensifying Competition in an Untreated Market

FSHD affects approximately 870,000 people globally, but no disease-modifying therapies have been approved by the FDA, EMA, or PMDA. The major markets in the U.S., EU5, and Japan are estimated to be worth about $600 million in 2025. Fulcrum Therapeutics' (FULC) p38α/β MAPK inhibitor losmapimod failed to meet its primary endpoint in the Phase 3 REACH trial in September 2024, leading to its discontinuation. Competitors include Novartis (NVS)'s DUX4-targeting antibody-oligonucleotide conjugate delpacibart braxlosiran (del-brax) in Phase 3, and Sarepta Therapeutics' (SRPT) DUX4-targeting siRNA SRP-1001 (formerly ARO-DUX4) in Phase 3, both acquired from Arrowhead Pharmaceuticals (ARWR). Scholar Rock's (SRRK) latent myostatin-targeting antibody apitegromab is also in Phase 2. To secure market leadership, EPI-321 must demonstrate both the durability of a single dose and functional efficacy.